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Short report
A training programme involving automatic
self-transcending meditation in late-life
depression: preliminary analysis of an ongoing
randomised controlled trial
Akshya Vasudev, Amanda Arena, Amer M. Burhan, Emily Ionson, Hussein Hirjee, Pramudith Maldeniya,
Stephen Wetmore and Ronnie I. Newman
Late-life depression affects 2–6% of seniors aged 60 years
and above. Patients are increasingly embracing non-
pharmacological therapies, many of which have not been
scientifically evaluated. This study aimed to evaluate a category
of meditation, automatic self-transcending meditation (ASTM), in
alleviating symptoms of depression when augmenting
treatment as usual (NCT02149810). The preliminary results of an
ongoing single-blind randomised controlled trial comparing a
training programme involving ASTM with a wait-list control
indicate that a 12-week ASTM programme may lead to
significantly greater reductions in depression and anxiety
severity. As such, ASTM may be an effective adjunctive therapy
in the treatment of late-life depression.
Declaration of interest
R.I.N. is Director of Research and Health Promotion for the Art
of Living Foundation, Canada and supervised the staff providing
ASTM training.
Copyright and usage
© The Royal College of Psychiatrists 2016. This is an open
access article distributed under the terms of the Creative
Commons Non-Commercial, No Derivatives (CC BY-NC-ND)
licence.
Major depressive disorder in seniors, described as late-life
depression, is a disabling condition afflicting 2–6% of the
population over age 60.1 Late-life depression leads to substantial
health and economic costs associated with elevated mortality rates
caused by cardiovascular episodes and high risk of suicide.1–2
Although antidepressants are the mainstay of treatment,
the response rate is only 30–40%,3 necessitating research on addi‐
tional non-pharmacological therapies. Automatic self-transcending
meditation (ASTM), a class of meditation, warrants further sci‐
entific evaluation. ASTM draws attention inward to quiet the
mind, and induces physiological and mental relaxation. The
practice involves relaxed attention to a specific sound value
(mantra); this permits the mind to experience a restful but alert
state of consciousness.4–6
The aim of this ongoing study is to evaluate the effectiveness
of ASTM in alleviating cardiovascular and mood-related symp-
toms of late-life depression (see Amtul et al7 for the complete
study protocol). This report presents the preliminary results of
adding ASTM to treatment-as-usual (TAU) on affective symp-
toms of late-life depression; an analysis of cardiovascular and
affective symptoms post-ASTM training will be available upon
study completion.
Method
Fifty-one participants 60–85 years of age enrolled in the study
(Fig. 1). This ongoing single-blind (assessor-blind) RCT compares
the addition of a 12-week training programme of ASTM to a TAU
wait-list group.
In our evaluation of ASTM for alleviating affective symptoms
of depression, the Hamilton Depression Rating Scale 17-item
version (HAM-D17)8 was set as the primary outcome measure.
Geriatric Depression Scale (GDS),9 Geriatric Anxiety Inventory
(GAI),10 Clinical Global Impression (CGI),11 Quality of Life
Profile Seniors Version (QOLSV),12 Toronto Side Effects Scale
(TSES)13 and the Physical Activity Scale for the Elderly (PASE)14
scores were considered secondary measures. Participants
were recruited from primary and secondary health centres in
London, Ontario, Canada; additionally, advertisements were
placed in community centres. Individuals interested in the
study were screened as per inclusion and exclusion criteria
(see below). Referring physicians were masked to treatment
allocations to minimise bias. Experimental methods were
approved by the University of Western Ontario’s Research Ethics
Board.
Inclusion and exclusion criteria
Potential participants completed an eligibility assessment upon
which the following criteria were met: participants were 60–85
years of age with a diagnosis of mild-to-moderate MDD due to
either unipolar depression or bipolar disorder; participant had a
current HAMD-17 score of 8–22; of good general physical health;
able to sit comfortably for 30–45 min without any major pain or
discomfort; have sufficient hearing to follow verbal instructions
when the eyes are closed; and willing to attend 75% of follow-up
appointments as an out-patient.
The following were exclusion criteria for the study: a diagnosis
of stroke, transient ischaemic attack, heart disease or a seizure in
the past year; head injury within the past 6 months; score less than
24 on the Mini-Mental State Examination; experiencing thoughts
of suicide at any stage of the study; other significant mental health
diagnoses. Additionally, individuals who practised any type of
meditation, mindfulness or breathing techniques regularly or who
were participating in similar studies did not qualify.
Treatment allocation and assessments
Participants were allocated with equal probability to the ASTM or
TAU study arms using online randomisation software.15 The
randomisation list was secured by a technician not directly
involved in the research, ensuring concealment of allocation
from assessors. The ASTM programme provided Sahaj Samadhi
195
BJPsych Open (2016)
2, 195–198. doi: 10.1192/bjpo.bp.115.002394
Meditation, taught by a certified instructor from the Art of Living
Foundation. It took place in groups of 3–8 participants on 4
consecutive days (2 h/day), followed by 11 one-hour weekly
‘reinforcement’ sessions. Participants were asked to independently
practise ASTM 20 min twice a day and to attend 75% of
reinforcement sessions.
Individuals in the TAU arm continued their existing treat-
ments, including antidepressants and/or psychotherapy, and
were offered the 4-day meditation training 12 weeks after the
inclusion.
All participants attended monthly assessments during
the study, where the aforementioned scales were adminis‐
tered by a trained rater, and any change in medication was
documented.
Results
Data are available from 47 participants (4 were excluded after
baseline data collection and last observation was carried forward
for all analyses). Participant demographics are presented in
Table 1.
Figure 2a presents mean HAM-D17 scores for each study arm.
Baseline HAM-D scores were comparable between the groups
(ASTM mean HAM-D score=14.5, s.d.=4.3; TAU mean HAM-D
score=15.7, s.d.=4.2). In the first 4 weeks, HAM-D scores on
average decreased by 3.3 points and 1.2 points in the ASTM and
TAU groups, respectively. At the end of 12 weeks, 50% of ASTM
participants achieved remission (defined as HAM-D17 score <8,
ASTM mean HAM-D=9.2, s.d.=4.3); only 9% of TAU participants
achieved remission (TAU mean HAM-D score=14.5, s.d.=4.8).
A 2×4 repeated-measures ANOVA with a Greenhouse–Geisser
correction identified significant changes in HAM-D17 score over
the 12-week period (F(2.489, 112.027)=14.986, P<0.001, ηp
2=0.250).
Importantly, there was a significant interaction between HAM-D
score and condition, with ASTM participants demonstrating the
largest reductions in depression severity over time (F(2.489,
112.027)=5.178, P<0.05, ηp
2=0.103). There was also a significant
main effect of condition, F(1, 45)=8.240, P<0.05, ηp
2=0.155.
Figures 2b and 2c show scores on the GDS and GAI findings
respectively. For both scales, 2×4 repeated-measures ANOVA
identified significant changes in score over time (GDS: F(2.507,
159 potential participants
contacted
86 eligible
51 enrolled
• 26 in the ASTM arm
• 25 in the TAU arm
47 attended baseline assessment
• 24 in the ASTM arm
• 23 in the TAU arm
42 completed 12-week study
• 20 in the ASTM arm
• 22 in the TAU arm
     5 withdrew after attending baseline assessments
• in the ASTm arm 4 withdrew
      1 withdrew on the advice of a psychiatrist, 1 withdrew because of back injury,
      2 withdrew for unknown reasons
• in the TAU arm 1 withdrew
      1 was withdrawn after being lost to follow-up (no return phone calls)
     4 excluded after enrolment
• in the ASTM arm 2 were excluded after enrolment
      1 withdrew as they were no longer willing to participate, 1 withdrew
       because of a spine injury
• in the TAU arm 2 were excluded after enrolment
      both were no longer depressed at the time of baseline
    35 excluded after being determined as eligible
• 24 no longer interested
      7 time commitment and time conflicts, 1 wanted to be paid more money,
      1 transportation issues, 1 travel, 1 health reasons, 13 no reson given
• 11 no longer depressed
      7 attended screenings and were found to be no longer depressed or
      HAM-D scores were too low, 4 expressed they were feeling better before
      the screening and no longer depressed
     73 excluded
• 21 not interested
      1 location, 3 time commitment, 1 only interested in afternoon
      appointments, 3 travel plans, 1 transportation issues, 11 no reason
      given, 1 health concerns
• 52 did not meet criteria
      33 not depressed/did not meet depression criteria, 2 recent meditation
      training, 6 too young, 4 lost to follow-up (wrong number or no return
      calls), 1 mobility, 6 health reasons (1 blood pressure disorder, 1
      Parkinson’s, 3 PTSD, 1 general poor health/unknown)
1
Fig. 1 CONSORT diagram.
Table 1 Selected demographic data
ASTM TAU P P
Age (s.d.) 68.33 (6.12) 66.95 (6.31) 0.471 0.471
Gender
Female 14 18 0.058
Male 11 4
Demographic data were collected for all participants who completed baseline. The
mean age between treatment arms was not significantly different as assessed by a
two-tailed t-test α=0.05. The gender distribution was not significantly different
between treatment arms as assessed by a chi-square test α=0.05.
Vasudev et al
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112.834)=7.073, P=0.001, ηp
2=0.136; GAI: F(2.414, 108.614)
=5.413, P<0.05, ηp
2=0.107), as well as interactions between score
and condition (GDS: F(2.507, 112.834)= 2.970, P<0.05, ηp
2=0.062;
GAI: F(2.414, 108.614)=2.946, P<0.05, ηp
2=0.061).
The CGI-I scale indicated a significant effect of study arm, with
ASTM participants improving through the study (F(1, 45)=8.137,
P<0.001, ηp
2=0.153). There was also a significant score over time
(F(2.218, 99.797)=123.924, P<0.001, ηp
2=0.734) and a CGI-I score x
condition interaction (F(1, 45)=19.422, P<0.001, ηp
2=0.153).
QOLSV scores improved over time (F(3, 135)=4.032, P<0.05,
ηp
2=0.082), regardless of treatment arm, with no significant
between-subjects differences.
There were no demonstrable physical activity level changes or
perceived side-effects as measured by PASE and TSES,
respectively.
Discussion
Preliminary results suggest that ASTM in addition to existing
treatments reduces depression and anxiety severity, compared
with treatment with antidepressants and/or psychotherapies only.
This study is ongoing, and completion is expected in 2016.
Late-life depression-specific standardised and validated observer-
rated and self-rated outcome measures ensured reliability and
generalisability of our data. Preliminary results suggest physical
activity level did not mediate ASTM group improvement. Con-
sonant with numerous studies of ASTM in both psychiatric16–19
and non-clinical populations,20,21 neither the frequency nor the
severity of potential adverse events, measured by the TSES,
suggests ASTM was unsafe. Like previous ASTM studies,22
compliance was high, and the mean dropout rate was 17.6%
(22.2% in ASTM arm and 12.5% in TAU), with no dropouts
related to adverse events (see Fig. 1).
Clinicians should remain cognisant of meditation categories
(e.g. concentration, open monitoring and ASTM) and their
indications for specific mental health conditions. Of these, mind-
fulness has been found effective for relapse prevention in
populations with depression;23 its efficacy as a treatment for
depression remains equivocal.24 The present study provides
insight into the applicability of a less frequently utilised, yet
highly promising meditation category for the treatment of late-life
depression.
A study limitation is the comparison of the ASTM training
programme with a wait-list control. Ideally, ASTM would be
compared with an active control that is similar in format
(i.e. group setting, regular contact with a trainer) and time
commitment. However this study’s aim was to assess whether
this technique and associated programme provided any additional
benefit compared with TAU. We took measures to reduce
risk of bias in this study: assessors were masked to allocation;
intention-to-treat analysis was used; the results for all mental
health measures have been reported. This study is not free of
selection or performance biases, and such biases are difficult to
reduce in such an RCT. Future research should focus on
comparing this technique with active controls such as mindful‐
ness meditation and cognitive behavioural therapy, so as to
disentangle the potential confounding effects of social inclusion
or performance bias from any specific benefits of the ASTM
technique itself.
These preliminary results demonstrate that an ASTM training
programme shows great promise as an adjunctive treatment for
late-life depression.
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Fig. 2 (a) Mean HAM-D17 score for ASTM and TAU study arms
presented at each assessment interval. (b) Mean self-rated GDS
score. (c) Mean self-rated GAI score. Error bars represent ±1 s.e.m.
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